Chk2 sustains PLK1 activity in mitosis to ensure proper chromosome segregation

Elizabeth M. Black,Carlos Andrés Ramírez Parrado,Isabelle Trier,Wenxue Li,Yoon Ki Joo,Jennifer Pichurin,Yansheng Liu,Lilian Kabeche

DOI: https://doi.org/10.1101/2024.03.08.584115

2024-03-12

Abstract:Polo-like kinase 1 (PLK1) protects against genome instability by ensuring timely and accurate mitotic cell division. PLK1 activity is tightly regulated throughout the cell cycle. Although the pathways that initially activate PLK1 in G2 are well-characterized, the factors that directly regulate PLK1 in mitosis remain poorly understood. Here, we identify that human PLK1 activity is sustained by the DNA damage response kinase Checkpoint kinase 2 (Chk2) in mitosis. Chk2 directly phosphorylates PLK1 T210, a residue on its T-loop whose phosphorylation is essential for full PLK1 kinase activity. Loss of Chk2-dependent PLK1 activity causes increased mitotic errors, including chromosome misalignment, chromosome missegregation, and cytokinetic defects. Moreover, Chk2 deficiency increases sensitivity to PLK1 inhibitors, suggesting that Chk2 status may be an informative biomarker for PLK1 inhibitor efficacy. This work demonstrates that Chk2 sustains mitotic PLK1 activity and protects genome stability through discrete functions in interphase DNA damage repair and mitotic chromosome segregation.

Cell Biology

What problem does this paper attempt to address?

The paper attempts to address the issue of how Checkpoint kinase 2 (Chk2) maintains the activity of Polo-like kinase 1 (PLK1) during mitosis and protects genomic stability through this mechanism.

Specifically:
1. **Importance of PLK1**: PLK1 is crucial for ensuring timely and accurate mitosis, but its regulatory mechanisms during mitosis are not fully understood.
2. **Role of Chk2**: The study found that Chk2 directly phosphorylates the T210 site of PLK1 during mitosis, a modification that is essential for PLK1 activity.
3. **Genomic Stability**: A decrease in Chk2-dependent PLK1 activity leads to mitotic errors, including chromosome misalignment, abnormal chromosome segregation, and cytokinesis defects.
4. **Clinical Significance**: The status of Chk2 may serve as a biomarker for evaluating the efficacy of PLK1 inhibitors, with Chk2 deficiency increasing cell sensitivity to low doses of PLK1 inhibitors.

In summary, the study reveals a new mechanism by which Chk2 maintains PLK1 activity during mitosis through direct action and highlights the importance of this pathway for genomic stability and cancer therapy.